Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the provided label excerpts (active ingredient identity and antiplatelet mechanism; indication related to NSTE-ACS/ACS and thrombotic event reduction). Claims about “generic version marketed under the generic name tirofiban” are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Aggrastat’s generic name is tirofiban.
Label active ingredient: tirofiban hydrochloride (Drug/Active ingredient(s) provided).
Aggrastat (tirofiban) is an antiplatelet medication.
12.1 Mechanism of Action: inhibits platelet aggregation.
Aggrastat (tirofiban) is used to help prevent blood clots in certain heart-related conditions.
1 INDICATIONS AND USAGE: reduces thrombotic cardiovascular events; Clinical Pharmacology describes inhibition of platelet aggregation.
Aggrastat (tirofiban) is used in suspected or confirmed acute coronary syndrome.
1 INDICATIONS AND USAGE: indicated for NSTE-ACS.
The generic version of Aggrastat has the same active ingredient as brand-name Aggrastat (tirofiban).
Active ingredient provided for AGGRASTAT is tirofiban hydrochloride (Drug/Active ingredient(s) provided).
Unsupported Statements
The generic version of Aggrastat is marketed under the generic name tirofiban.
The provided label excerpts do not state how any generic product is marketed/named (label does not include generic marketing statements).
Contradictions
Important Omissions
No dosing/administration, contraindications, boxed warnings, or key monitoring information was provided in the claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily identity/therapeutic-area statements. No dosing, contraindications, warnings, or interaction guidance was provided, so risk from incorrect label-aligned detail is limited to the single unsupported generic-marketing claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Generic-product marketing/naming statement is not supported by the provided label excerpts.
Suggested Improvement
Remove or rephrase the generic marketing claim; keep to label-supported facts (active ingredient tirofiban; mechanism inhibits platelet aggregation; indication for NSTE-ACS to reduce thrombotic cardiovascular events).